Table 3.
HDL-C, ApoA-I, HDL-C/ApoA-I ratio and HDL diameters computed with Eq. 1 (dWHS) and measured (dmeas) in populations with CETP deficiency and/or treated with CETP Inhibitors.
| Population/Treatment Regimen (n) | Ref. | HDL-C a (mg/dL) | ApoA-I a (mg/dL) | HDL-C/ApoA-I (dimensionless) | dWHS (nm) | dmeas a (nm) |
|---|---|---|---|---|---|---|
| CETP homozygotes (n=4) | 16 | 193 ± 28 | 233.5 ± 22.3 | 0.827 | 14.8 | 14.5 ± 1.0 b |
| CETP homozygotes (n=15) | 16 | 84 ± 25 | 155.3 ± 22.1 | 0.541 | 11.3 | 11.8 ± 0.6 b |
| Normal Controls (n=20) | 16 | 50 ± 8 | 140.9 ± 16.1 | 0.355 | 9.0 | 10.5 ± 0.1 b |
| Torcetrapib 120 mg BID × 4 wk (n=6) | 17 | 70 ± 15 | 151 ± 6 | 0.464 | 10.4 | 9.7 ± 0.7 c |
| Baseline (n=6) | 17 | 34 ± 5 | 112 ± 13 | 0.304 | 8.4 | 8.4 ± 0.4 c |
| Dalcetrapib 900 mg QD × 12 wk (n=72) | 18 d | 51.5 ± 12.5 | 147.2 ± 27.1 | 0.349 | 9.0 | 8.9 ± 0.4 c |
| Dalcetrapib 600 mg QD × 12 wk (n=67) | 18 d | 50.5 ± 10.7 | 149.2 ± 25.0 | 0.338 | 8.8 | 8.8 ± 0.4 c |
| Dalcetrapib 300 mg QD × 12 wk (n=75) | 18 d | 44.0 ± 9.4 | 137.7 ± 22.1 | 0.320 | 8.6 | 8.6 ± 0.3 c |
| Placebo (n=73) | 18 d | 39.2 ± 7.2 | 132.2 ± 19.1 | 0.296 | 8.3 | 8.4 ± 0.3 c |
| Anacetrapib 100 mg QD × 76 wk (n=541) | 19 | 102.3 | 203 | 0.504 | 10.9 | NR e |
| Baseline (n=797) | 19 | 40.5 | 142.5 | 0.284 | 8.2 | NR e |
a
Mean ± SD (where available).
b
measured by Gel Permeation Chromatography (GPC);
c
measured by NMR spectroscopy;
d
HDL size measurements corresponding to ref. 18 were supplied by Dr. David Kallend, from data on file F. Hoffmann-LaRoche, Ltd.;
e
NR = not reported